GEMCOVAC –OM Vaccine

About GEMCOVAC –OM Vaccine:

• It was developed using the indigenous platform technology by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC).
• It is a thermo-stable vaccine, which does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India.
• It is delivered intra-dermally using a needle-free injection device system.
• When administered intradermally in participants as a booster, it generated significantly higher immune responses.
• The clinical outcome demonstrates the need for variant-specific vaccines for desired immune response.

Key facts about BIRAC

• It is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by the Department of Biotechnology (DBT), Government of India,
• It is an Interface Agency to strengthen and empower emerging Biotech enterprises to undertake strategic research and innovation, addressing nationally relevant product development needs.

What is mRNA vaccine?

• It contains messenger RNA (mRNA), a single-stranded RNA molecule that complements DNA.
• It is created in the nucleus when DNA is transcribed by RNA polymerase to create pre-mRNA

Q1) What is cell nucleus?

In biology, the nucleus is a membrane-bound organelle found in eukaryotic cells. It is often referred to as the “control center” of the cell because it houses the genetic material and regulates cellular activities.

Source: Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology

‹ ›